# Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis

> **NCT06723171** · PHASE2 · SUSPENDED · sponsor: **Io Therapeutics** · enrollment: 20 (estimated)

## Conditions studied

- Psoriasis
- Plaque Type Psorisis
- Plaque Psoriasis

## Interventions

- **DRUG:** IRX4204
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06723171
- **Lead sponsor:** Io Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-03-01
- **Primary completion:** 2026-03
- **Final completion:** 2026-04
- **Target enrollment:** 20 (ESTIMATED)
- **Why stopped:** Sponsor request for study hold
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723171, "Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06723171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*